Business Description
Aura Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US05153U1079
Total Employee Number:
113Description
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 6.75 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | -0.15 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 2.1 | |||||
3-Year EPS without NRI Growth Rate | 3.3 | |||||
3-Year FCF Growth Rate | 8.8 | |||||
3-Year Book Growth Rate | -25.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 3.78 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.89 | |||||
9-Day RSI | 46.73 | |||||
14-Day RSI | 47.79 | |||||
3-1 Month Momentum % | -10 | |||||
6-1 Month Momentum % | 20.24 | |||||
12-1 Month Momentum % | -9.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.09 | |||||
Quick Ratio | 7.09 | |||||
Cash Ratio | 6.87 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -19 | |||||
Shareholder Yield % | 0.18 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.89 | |||||
ROA % | -65.58 | |||||
ROIC % | -425.32 | |||||
3-Year ROIIC % | 1297.8 | |||||
ROC (Joel Greenblatt) % | -625.64 | |||||
ROCE % | -76.43 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.1 | |||||
Price-to-Tangible-Book | 4.09 | |||||
EV-to-EBIT | -5.14 | |||||
EV-to-EBITDA | -5.19 | |||||
EV-to-Forward-Revenue | 9.04 | |||||
EV-to-FCF | -6.65 | |||||
| Price-to-Net-Current-Asset-Value | 4.99 | |||||
| Price-to-Net-Cash | 5.22 | |||||
Earnings Yield (Greenblatt) % | -19.46 | |||||
FCF Yield % | -12.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AURA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aura Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.74 | ||
| Beta | 0.8156 | ||
| 3-Year Sharpe Ratio | -0.34 | ||
| 3-Year Sortino Ratio | -0.48 | ||
| Volatility % | 30.15 | ||
| 14-Day RSI | 47.79 | ||
| 14-Day ATR ($) | 0.503795 | ||
| 20-Day SMA ($) | 6.82625 | ||
| 12-1 Month Momentum % | -9.6 | ||
| 52-Week Range ($) | 4.73 - 9.535 | ||
| Shares Outstanding (Mil) | 103.44 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aura Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aura Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 125 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 33 days | ||
| General meeting for 2026 | 2026-06-11 09:30 | 6.12 (-3.47%) | ||
| TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA | 2026-05-27 13:30 | 7.61 (-0.52%) | ||
| H.C. Wainwright 4th Annual BioConnect Investor Conference | 2026-05-19 12:00 | 7.47 (-3.11%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 8.40 (+3.07%) | ||
| Annual report for 2025 | 2026-03-30 | 6.27 (-1.88%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-30 | 6.27 (-1.88%) | ||
| The Citizens Life Sciences Conference | 2026-03-11 11:20 | 5.64 (+0.36%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 15:40 | 5.67 (+1.80%) |
Show
Entries
Aura Biosciences Inc Frequently Asked Questions
What is Aura Biosciences Inc(AURA)'s stock price today?
The current price of AURA is $6.84. The 52 week high of AURA is $9.54 and 52 week low is $4.73.
When is next earnings date of Aura Biosciences Inc(AURA)?
The next earnings date of Aura Biosciences Inc(AURA) is 2026-08-13 Est..
Does Aura Biosciences Inc(AURA) pay dividends? If so, how much?
Aura Biosciences Inc(AURA) does not pay dividend.
Guru Commentaries on NAS:AURA
No articles.
Press Release
Articles on Aura Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers